Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - carvedilolum inn - tafla - 12,5 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - carvedilolum inn - tafla - 6,25 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - letrozolum inn - filmuhúðuð tafla - 2,5 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 10 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 5 mg

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - Æxlishemjandi lyf - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, meðferð - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - rasilamlo er ætlað til meðhöndlunar á nauðsynlegum háþrýstingi hjá fullorðnum sjúklingum, þar sem blóðþrýstingur er ekki nægilega stjórnað með aliskireni eða amlodipini sem er notað eitt sér.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, meðferð, sýnt fram á að hjá - háþrýstingur - hjarta og æðakerfi - rasitrio er ætlað til meðferð við háþrýstingi eins og stað meðferð í fullorðinn sjúklingar sem blóðþrýstingur er nægilega stjórn á sambland af aliskiren, meðferð og sýnt fram á að hjá gefið samtímis á sama skammti eins og í samsetning.